ArticleAMB Express2025
Phage receptor binding protein and Fc fragment fusion enhances phagocytosis of Y. enterocolitica.
Article in AMB Express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular diversity and evolutionary dynamics of phage receptor binding proteins in Staphylococcus aureus: implications for phage therapy and resistance.Scientific reports · 2026Article
- Key directions of fundamental research on bacteriophage Receptor Binding Proteins with applied potential.Frontiers in microbiology · 2026Review
- Genomic characterization ofFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Bacteriophage receptor binding proteins (RBPs) belong to a group of proteins that are components of the bacteriophage tail. RBPs are mainly responsible for recognizing receptors on the bacterial host surface and enabling infection and subsequent progeny phage multiplication. Our previous research suggested that recombinant tail fiber gp17 (TFPgp17) protein from Yersinia enterocolitica phage φYeO3-12 recognizes serotype O:3 with high specificity and could be used as a diagnostic tool. In this paper, we study the possibility of using modified TFPgp17 in fusion with IgG1 Fc immunoglobulin fragment (Fc_TFPgp17) to improve the efficacy of pathogen recognition by phagocytic cells, opsonization of bacterial cells, and then phagocytosis by the THP-1 macrophages and the HL-60 neutrophils. We demonstrate that the Fc_TFPgp17 protein can bind both bacterial and phagocytic cells, due to the presence of the RBP domain and the IgG1 Fc fragment, respectively. Additionally, it contributes to the better recognition of bacterial cells and their subsequent phagocytosis by phagocytes. Additionally, we proved that glycosylation of Fc_TFPgp17 which occurred during protein production, harms the ability to recognize Y. enterocolitica O:3. Fc_TFPgp17 is a bispecific protein that possesses two biological functions: (I) recognized Y. enterocolitica O:3 cells via phage RBP (TFPgp17) and (II) recognized phagocytic cells via Fc-fragment IgG1 immunoglobulin. In this work, we demonstrated that the recombined bispecific protein facilitates more effective recognition and opsonization of the pathogenic bacterial cell, leading to its subsequent phagocytosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.